Telitacicept for IgA nephropathy: a systematic review and meta-analysis of observational studies
{{output}}
Background: Telitacicept, a dual BAFF/APRIL inhibitor, is a potential targeted therapy for IgA nephropathy (IgAN), but its real-world efficacy and safety remain unclear. ... ...
